ID   LNCaP C-51
AC   CVCL_M130
SY   LNCaP-C51 C-51; C51
DR   cancercelllines; CVCL_M130
DR   Wikidata; Q54902823
RX   PubMed=11705865;
RX   PubMed=11870800;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M129 ! LNCaP C-33
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 16
//
RX   PubMed=11705865;
RA   Karan D., Schmied B.M., Dave B.J., Wittel U.A., Lin M.-F., Batra S.K.;
RT   "Decreased androgen-responsive growth of human prostate cancer is
RT   associated with increased genetic alterations.";
RL   Clin. Cancer Res. 7:3472-3480(2001).
//
RX   PubMed=11870800; DOI=10.1002/pros.10054;
RA   Igawa T., Lin F.-F., Lee M.-S., Karan D., Batra S.K., Lin M.-F.;
RT   "Establishment and characterization of androgen-independent human
RT   prostate cancer LNCaP cell model.";
RL   Prostate 50:222-235(2002).
//